Elevance Health Valuation
Is ELV * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ELV * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ELV * (MX$9098) is trading below our estimate of fair value (MX$19440.92)
Significantly Below Fair Value: ELV * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ELV *?
Other financial metrics that can be useful for relative valuation.
What is ELV *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$122.85b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.8x |
Enterprise Value/EBITDA | 12.8x |
PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does ELV *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 20.2x | ||
CNC Centene | 14.1x | 9.1% | US$39.0b |
HUM Humana | 19x | 14.3% | US$36.4b |
UNH UnitedHealth Group | 29x | 19.1% | US$445.0b |
MOH Molina Healthcare | 18.5x | 16.1% | US$20.0b |
ELV * Elevance Health | 19.5x | 12.5% | Mex$122.9b |
Price-To-Earnings vs Peers: ELV * is good value based on its Price-To-Earnings Ratio (19.5x) compared to the peer average (20.2x).
Price to Earnings Ratio vs Industry
How does ELV *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: ELV * is good value based on its Price-To-Earnings Ratio (19.5x) compared to the Global Healthcare industry average (21.3x).
Price to Earnings Ratio vs Fair Ratio
What is ELV *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 19.5x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ELV *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$10,235.56 0% | 5.6% | Mex$11,354.28 | Mex$8,878.53 | n/a | 19 |
Apr ’25 | n/a | Mex$9,548.50 0% | 4.2% | Mex$10,456.62 | Mex$8,644.58 | n/a | 19 |
Mar ’25 | n/a | Mex$9,765.21 0% | 4.2% | Mex$10,734.89 | Mex$8,874.63 | n/a | 17 |
Feb ’25 | n/a | Mex$9,763.70 0% | 4.3% | Mex$10,821.32 | Mex$8,946.08 | n/a | 16 |
Jan ’25 | n/a | Mex$9,714.97 0% | 4.1% | Mex$10,855.66 | Mex$8,974.47 | n/a | 17 |
Dec ’24 | n/a | Mex$9,736.53 0% | 4.7% | Mex$10,834.46 | Mex$8,956.95 | n/a | 17 |
Nov ’24 | Mex$8,275.00 | Mex$10,252.97 +23.9% | 4.6% | Mex$11,388.99 | Mex$9,415.38 | n/a | 17 |
Oct ’24 | n/a | Mex$9,764.58 0% | 4.3% | Mex$10,772.32 | Mex$8,905.57 | n/a | 19 |
Sep ’24 | Mex$7,535.00 | Mex$9,764.44 +29.6% | 4.3% | Mex$10,754.39 | Mex$8,890.75 | n/a | 20 |
Aug ’24 | Mex$7,977.09 | Mex$9,589.09 +20.2% | 4.5% | Mex$10,592.80 | Mex$8,757.16 | n/a | 20 |
Jul ’24 | Mex$7,519.53 | Mex$9,569.31 +27.3% | 8.1% | Mex$10,591.15 | Mex$6,833.00 | n/a | 22 |
Jun ’24 | Mex$7,763.03 | Mex$10,030.20 +29.2% | 7.7% | Mex$11,037.67 | Mex$7,121.08 | n/a | 22 |
May ’24 | Mex$8,425.13 | Mex$10,117.70 +20.1% | 7.8% | Mex$11,147.54 | Mex$7,191.96 | n/a | 22 |
Apr ’24 | Mex$8,135.11 | Mex$10,256.41 +26.1% | 8.7% | Mex$11,300.37 | Mex$7,290.56 | n/a | 22 |
Mar ’24 | Mex$8,474.05 | Mex$10,421.11 +23.0% | 9.1% | Mex$11,386.61 | Mex$7,346.20 | n/a | 21 |
Feb ’24 | Mex$9,409.07 | Mex$10,659.12 +13.3% | 9.2% | Mex$11,636.90 | Mex$7,507.68 | n/a | 21 |
Jan ’24 | n/a | Mex$11,035.28 0% | 7.0% | Mex$12,501.25 | Mex$9,336.87 | n/a | 20 |
Dec ’23 | n/a | Mex$10,885.71 0% | 6.7% | Mex$12,381.12 | Mex$9,247.15 | n/a | 20 |
Nov ’23 | Mex$10,620.41 | Mex$11,180.06 +5.3% | 6.7% | Mex$12,749.89 | Mex$9,522.57 | Mex$8,275.00 | 20 |
Oct ’23 | Mex$9,178.17 | Mex$10,816.63 +17.9% | 10.8% | Mex$12,131.07 | Mex$6,662.15 | n/a | 21 |
Sep ’23 | n/a | Mex$10,921.08 0% | 10.8% | Mex$12,291.26 | Mex$6,750.12 | Mex$7,535.00 | 21 |
Aug ’23 | Mex$9,461.12 | Mex$10,998.03 +16.2% | 11.1% | Mex$12,691.81 | Mex$6,802.81 | Mex$7,977.09 | 22 |
Jul ’23 | Mex$9,795.16 | Mex$11,076.83 +13.1% | 12.7% | Mex$12,860.54 | Mex$6,710.72 | Mex$7,519.53 | 23 |
Jun ’23 | Mex$10,000.00 | Mex$11,037.13 +10.4% | 13.0% | Mex$12,698.63 | Mex$6,626.23 | Mex$7,763.03 | 22 |
May ’23 | n/a | Mex$11,299.62 0% | 13.6% | Mex$13,102.39 | Mex$6,836.91 | Mex$8,425.13 | 21 |
Analyst Forecast: Target price is less than 20% higher than the current share price.